Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06957821
EARLY_PHASE1

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries. The investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

25

Start Date

2026-02-28

Completion Date

2027-12-31

Last Updated

2026-01-14

Healthy Volunteers

No

Interventions

DRUG

Pegulicianine

Pegulicianine (LUMISIGHT) Inflammatory activity

OTHER

Placebo

Control group for the study

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States